News

FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma

01/22/2021

The FDA has approved nivolumab plus cabozantinib for patients with advanced renal cell carcinoma.

The FDA has approved nivolumab...

01/22/2021

Oncology

News

ctDNA Feasible, Accurately Detects Genomic Alterations in Metastatic RCC

01/13/2021

A study including the largest metastatic RCC cohort to date has shown that ctDNA testing is viable and efficient for detecting genomic alterations in this patient population.

A study including the largest...

01/13/2021

Oncology

News

Real-World Study Shows Cabozantinib Effective for Pretreated mRCC

01/07/2021

In the largest real-world study to date, researchers found cabozantinib effective in treating heavily pretreated patients with metastatic RCC.

In the largest real-world study...

01/07/2021

Oncology

News

ICI Rechallenge Shows Moderate Efficacy for Treatment of mRCC

11/06/2020

Findings from a cohort study show ICI rechallenge yields reasonable safety and efficacy in patients with metastatic RCC.

Findings from a cohort study...

11/06/2020

Oncology

News

Pazopanib After ICIs Improves PFS, ORR in Metastatic Renal Cell Carcinoma

10/15/2020

Results from a phase II trial showed promising activity in pazopanib when given to mRCC patients after receiving ICIs.

Results from a phase II trial...

10/15/2020

Oncology

News

Higher Safety, Efficacy With Savolitinib vs Sunitinib for Papillary RCC

09/18/2020

The SAVOIR phase 3 trial showed patients with PRCC who received savolitinib had a higher overall survival and experienced fewer adverse effects than those given sunitinib.

The SAVOIR phase 3 trial showed...

09/18/2020

Oncology

News

Salvage Ipilimumab Plus Nivolumab Active in Metastatic RCC

07/29/2020

Ipilimumab plus nivolumab yielded anti-tumor activity with acceptable toxicity in patients with metastatic RCC previously given immune checkpoint inhibitors.

Ipilimumab plus nivolumab...

07/29/2020

Oncology

News

Pembrolizumab Plus Bevacizumab Safe, Effective for Metastatic RCC

03/11/2020

Pembrolizumab combined with bevacizumab was shown to be safe and active in a study of patients with metastatic clear cell RCC.

Pembrolizumab combined with...

03/11/2020

Oncology

News

Cancer Tumor Growth Rates Vary by Genetic Subtype

03/06/2020

Researchers have found that tumor growth rates vary based on genetic subtype, and support the use of frequent or extended surveillance for different situations.

Researchers have found that...

03/06/2020

Oncology

News

Lenvatinib Plus Pembrolizumab Promising for RCC and Other Solid Tumors

02/28/2020

Study findings suggest that lenvatinib plus pembrolizumab has promising antitumor activity and a manageable safety profile in patients with solid tumor types.

Study findings suggest that...

02/28/2020

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology